Scientific Publications

  1. September 2026, Buchan SA, Xie J, Bhatt M, et al. Respiratory Syncytial Virus–Related Hospitalizations Among Infants Receiving Nirsevimab. JAMA Netw Open. 2026;9(9):e2633621. doi:10.1001/jamanetworkopen.2026.33621
  2. September, 2026 Bemmo, A., Fortin, É., Fortin, P., Doggui, R., Guay, C.-A., Amini, R., Carazo, S., Papenburg, J., & Gilca, R. (2026). Impact of the first nirsevimab immunization campaign on infant RSV-related emergency department visits and hospitalizations in Québec, Canada Epidemiology https://doi.org/10.1097/EDE.0000000000002050
  3. May 2026, Razzini J, Giné-Vázquez I, Jin J et al.Impact of universal nirsevimab prophylaxis in infants on hospital and primary care outcomes across two respiratory syncytial virus seasons in Galicia, Spain (NIRSE-GAL): a population-based prospective observational study The Lancet Infectious Diseases, 2026; 26, 522-534
  4. December 2025, Moline HL, Tannis A, Goldstein L, et al. Effectiveness and Impact of Maternal RSV Immunization and Nirsevimab on Medically Attended RSV in US Children. JAMA Pediatr. 2026;180(3):314–324. doi:10.1001/jamapediatrics.2025.5778
  5. December 2025, Jabagi M, Bertrand M, Gabet A, Kolla E, Olié V, Zureik M. Nirsevimab vs RSVpreF Vaccine for Respiratory Syncytial Virus–Related Hospitalization in Newborns. JAMA. 2026;335(9):787–798. doi:10.1001/jama.2025.24082
  6. December 2025, Marina Viñeta Páramo, MBBS Jeffrey Man Hay Wong, MD Pascal M. Lavoie, MDCM, PhD RSV immunization in pregnancy and infancy, BCMJ
  7. November 2025, Vadlamudi N, Gomes K, Chow E et al. Healthcare costs and resource utilization for acute respiratory syncytial virus pediatric hospitalizations in Canada: a population-based study The Lancet Regional Health – Americas, 2025; 51
  8. September 2025, Pérez Marc G, Vizzotti C, Fell D et al. Real-world effectiveness of RSVpreF vaccination during pregnancy against RSV-associated lower respiratory tract disease leading to hospitalisation in infants during the 2024 RSV season in Argentina (BERNI study): a multicentre, retrospective, test-negative, case–control study, The Lancet Infectious Diseases, 2025; 25, 1044-1054
  9. July 2025, Buttarelli L, Caselli E, Gerevini S, Leuratti P, Gambadauro A, Manti S, Esposito S. Predictive Factors and Clinical Markers of Recurrent Wheezing and Asthma After RSV Infection. Viruses. 2025 Jul 31;17(8):1073. doi: 10.3390/v17081073. PMID: 40872787; PMCID: PMC12390669.
  10. May 2024, Beusterien, K. M., Law, A. W., Maculaitis, M. C., Will, O., Kopenhafer, L., Olsen, P., Hauber, B., Vietri, J. T., Cappelleri, J. C., Coulter, J. R., & Shea, K. M. (2024). Healthcare Providers’ and Pregnant People’s Preferences for a Preventive to Protect Infants from Serious Illness Due to Respiratory Syncytial Virus. Vaccines, 12(5), 560.
  11. Maternal vaccination to prevent severe RSV disease in infants
  12. Respiratory syncytial virus vaccination in pregnancy (cmaj.ca)
  13. Nirsevimab to reduce infant morbidity from respiratory syncytial virus (cmaj.ca)
  14. New RSV vaccine could prevent 5,000 infant hospitalisations – GOV.UK (www.gov.uk)
  15.  Acceptance and preference between respiratory syncytial virus vaccination during pregnancy and infant monoclonal antibody among pregnant and postpartum persons in Canada – ScienceDirect
  16. Efficacy, Safety, and Immunogenicity of the MATISSE (Maternal Immunization Study for Safety and Efficacy) Maternal Respiratory Syncytial Virus Prefusion F Protein Vaccine Trial
  17. Preterm Birth Frequency and Associated Outcomes From the MATISSE (Maternal Immunization Study for Safety and Efficacy) Maternal Trial of the Bivalent Respiratory Syncytial Virus Prefusion F Protein Vaccine 
  18. High Uptake of Respiratory Syncitial Virus Prevention for Neonates in a Military Treatment Facility – ScienceDirect